These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8804378)

  • 1. Endpoints and clinical trial design for nonalcoholic steatohepatitis.
    Sanyal AJ; Brunt EM; Kleiner DE; Kowdley KV; Chalasani N; Lavine JE; Ratziu V; McCullough A
    Hepatology; 2011 Jul; 54(1):344-53. PubMed ID: 21520200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic steatohepatitis (NASH): why biopsy?
    McNair A
    Gut; 2002 Dec; 51(6):898; author reply 898-9. PubMed ID: 12427803
    [No Abstract]   [Full Text] [Related]  

  • 3. Transcriptomics-driven metabolic pathway analysis reveals similar alterations in lipid metabolism in mouse MASH model and human.
    Tsouka S; Kumar P; Seubnooch P; Freiburghaus K; St-Pierre M; Dufour JF; Masoodi M
    Commun Med (Lond); 2024 Mar; 4(1):39. PubMed ID: 38443644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.
    Masoodi M; Gastaldelli A; Hyötyläinen T; Arretxe E; Alonso C; Gaggini M; Brosnan J; Anstee QM; Millet O; Ortiz P; Mato JM; Dufour JF; Orešič M
    Nat Rev Gastroenterol Hepatol; 2021 Dec; 18(12):835-856. PubMed ID: 34508238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes.
    Ichimori S; Shimoda S; Goto R; Matsuo Y; Maeda T; Furukawa N; Kawashima J; Kodama S; Sekigami T; Isami S; Nishida K; Araki E
    J Diabetes Investig; 2012 Mar; 3(2):179-84. PubMed ID: 24843563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the relationship between non-alcoholic fatty liver disease and CAD using MSCT.
    Efe D; Aygün F
    Arq Bras Cardiol; 2014 Jan; 102(1):10-8. PubMed ID: 24263777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the effects of a high-energy diet on fatty liver and hippocampal-dependent memory in male rats.
    Darling JN; Ross AP; Bartness TJ; Parent MB
    Obesity (Silver Spring); 2013 May; 21(5):910-7. PubMed ID: 23784893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heme oxygenase-1 mRNA expression in egyptian patients with chronic liver disease.
    Bessa SS; Mohamed Ali EM; Abd El-Wahab Ael-S; Nor El-Din SA
    Hepat Mon; 2012 Apr; 12(4):278-85. PubMed ID: 22690236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of therapy in nonalcoholic Fatty liver disease.
    McNear S; Harrison SA
    Therap Adv Gastroenterol; 2009 Jan; 2(1):29-43. PubMed ID: 21180532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis.
    Otogawa K; Kinoshita K; Fujii H; Sakabe M; Shiga R; Nakatani K; Ikeda K; Nakajima Y; Ikura Y; Ueda M; Arakawa T; Hato F; Kawada N
    Am J Pathol; 2007 Mar; 170(3):967-80. PubMed ID: 17322381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease and HIV infection.
    Merriman RB
    Curr HIV/AIDS Rep; 2006 Sep; 3(3):113-7. PubMed ID: 16970837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma arising from nonalcoholic steatohepatitis: report of two cases.
    Hai S; Kubo S; Shuto T; Tanaka H; Takemura S; Yamamoto T; Kanazawa A; Ogawa M; Hirohashi K; Wakasa K
    Surg Today; 2006; 36(4):390-4. PubMed ID: 16554999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease.
    Riley TR; Kahn A
    Dig Dis Sci; 2006 Jan; 51(1):41-4. PubMed ID: 16416209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis.
    Tous M; Ferré N; Camps J; Riu F; Joven J
    Mol Cell Biochem; 2005 Jan; 268(1-2):53-8. PubMed ID: 15724437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and risk factors of patients with fatty liver in Guangzhou area.
    Chen QK; Chen HY; Huang KH; Zhong YQ; Han JA; Zhu ZH; Zhou XD
    World J Gastroenterol; 2004 Mar; 10(6):899-902. PubMed ID: 15040041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients.
    Bahrami H; Daryani NE; Mirmomen S; Kamangar F; Haghpanah B; Djalili M
    BMC Gastroenterol; 2003 Oct; 3():27. PubMed ID: 14561231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cirrhosis with steatohepatitis following longterm stilboestrol treatment.
    Cooper L; Palmer M; Oien K
    J Clin Pathol; 2003 Aug; 56(8):639. PubMed ID: 12890826
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?
    Evans CD; Oien KA; MacSween RN; Mills PR
    J Clin Pathol; 2002 Sep; 55(9):689-92. PubMed ID: 12195000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic steatohepatitis.
    Neuschwander-Tetri BA; Bacon BR
    Med Clin North Am; 1996 Sep; 80(5):1147-66. PubMed ID: 8804378
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.